Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Celgene Corporation (CELG - Analyst Report) recently announced that data on its oncology drug Pomalyst (EU trade name: Imnovid) from a phase III study (MM-003: n=455) was published online in the Lancet Oncology.

The trial evaluated Pomalyst in combination with low-dose dexamethasone versus high-dose dexamethasone in relapsed and refractory multiple myeloma (MM) patients, who have received unsuccessfully at least 2 prior therapies (inclusive of Celgene’s key oncology drug Revlimid and Takeda Pharmaceutical Company’s Velcade administered either as a monotherapy or in conjunction with other therapy/ies) for the disease.

Data revealed that there was significant improvement in progression-free survival and overall survival in patients in the Pomalyst arm. Moreover, the data monitoring committee recommended that MM patients who have not yet responded to treatment by  dexamethasone (high dose) should have access to Pomalyst either in combination with  dexamethasone (low dose) or as a monotherapy.

We note that the drug was approved in the EU for the above indication on the basis of data from the MM-003 study. The EC cleared the drug for treating MM patients whose disease had worsened while on their last therapy.

We note that Pomalyst is already available in the U.S. for the MM indication. The U.S. Food and Drug Administration approved Pomalyst in Feb 2013. The drug is under review in many other countries. Approval in additional markets would boost Celgene’s top line further as the MM market offers significant commercial potential. U.S. sales of the oncology drug in the second quarter of 2013 (its first full quarter in the market) came in at $58 million.

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Actelion Ltd. (ALIOF) and Gilead Sciences Inc. (GILD - Analyst Report) appear to be well placed in the biopharma space with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%